<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02842697</url>
  </required_header>
  <id_info>
    <org_study_id>NanfangH</org_study_id>
    <nct_id>NCT02842697</nct_id>
  </id_info>
  <brief_title>Virtual Imaging-based Hepatic Venous Pressure Gradient (vHVPG) (CHESS1601)</brief_title>
  <acronym>vHVPG</acronym>
  <official_title>Virtual Imaging-based Hepatic Venous Pressure Gradient for Assessment of Clinically Significant Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center trial conducted at 1 Guangzhou and 2 Beijing centers
      designed to determine the diagnostic performance of virtual hepatic venous pressure gradient
      (vHVPG) (investigational technology) by anatomic computed tomographic angiography (CTA) for
      non-invasive assessment of the clinically significant portal hypertension (CSPH) in patients
      with compensated cirrhosis. Direct hepatic venous pressure gradient (HVPG) measurement by
      means of catheterization of a hepatic vein with a balloon catheter is the gold-standard
      method to assess the presence of CSPH, which is defined as HVPG≥10 mmHg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center trial conducted at 1 Guangzhou (Nanfang Hospital) and 2
      Beijing (Beijing 302 Hospital, Beijing Shijitan Hospital) centers designed to determine the
      diagnostic performance of vHVPG (investigational technology) by anatomic CTA for non-invasive
      assessment of the CSPH in patients with compensated cirrhosis. Direct HVPG measurement by
      means of catheterization of a hepatic vein with a balloon catheter is the gold-standard
      method to assess the presence of CSPH, which is defined as HVPG≥10 mmHg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy of vHVPG</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic accuracy of vHVPG to determine presence or absence of a CSPH when compared to HVPG as the reference standard (HVPG≥10mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Performance of vHVPG</measure>
    <time_frame>1 day</time_frame>
    <description>Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of vHVPG when compared to HVPG as the reference standard (HVPG≥10mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vHVPG Numerical Correlation</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation of the vHVPG numerical value with the HVPG numerical value</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Single arm study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.
Intervention: Procedure: HVPG measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HVPG measurement</intervention_name>
    <description>HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CTA</intervention_name>
    <description>Three-dimensional hepatic vein-portal vein model constructed with CTA images</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Doppler ultrasound</intervention_name>
    <description>Portal vein velocity measured by Doppler ultrasound</description>
    <arm_group_label>Single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Patients providing written informed consent

          -  Patients with compensated cirrhosis and scheduled to undergo clinically-indicated
             invasive HVPG measurement by means of catheterization of a hepatic vein with a balloon
             catheter

          -  Has undergone &gt; 64 multi-detector row CTA within 14 days prior to hepatic vein
             catheterization

          -  No hepatic-portal vein interventional therapy between the CTA and hepatic vein
             catheterization

        Exclusion Criteria:

          -  Prior transjugular intrahepatic portosystem stent-shunt surgery

          -  Prior devascularization operation

          -  Has received a liver transplant

          -  Patients with known anaphylactic allergy to iodinated contrast

          -  Pregnancy or unknown pregnancy status

          -  Patient requires an emergent procedure

          -  Any active, serious, life-threatening disease

          -  Inability to adhere to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Qi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </reference>
  <reference>
    <citation>de Franchis R, Dell'Era A. Invasive and noninvasive methods to diagnose portal hypertension and esophageal varices. Clin Liver Dis. 2014 May;18(2):293-302. doi: 10.1016/j.cld.2013.12.002. Epub 2014 Feb 25. Review.</citation>
    <PMID>24679495</PMID>
  </reference>
  <reference>
    <citation>Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013 Feb;7(2):141-55. doi: 10.1586/egh.12.83. Review.</citation>
    <PMID>23363263</PMID>
  </reference>
  <reference>
    <citation>Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012 Sep 26;308(12):1237-45.</citation>
    <PMID>22922562</PMID>
  </reference>
  <reference>
    <citation>Qi X, Li Z, Huang J, Zhu Y, Liu H, Zhou F, Liu C, Xiao C, Dong J, Zhao Y, Xu M, Xing S, Xu W, Yang C. Virtual portal pressure gradient from anatomic CT angiography. Gut. 2015 Jun;64(6):1004-5. doi: 10.1136/gutjnl-2014-308543. Epub 2014 Nov 14.</citation>
    <PMID>25398771</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>clinically significant portal hypertension</keyword>
  <keyword>hepatic venous pressure gradient</keyword>
  <keyword>computed tomographic angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

